Navigation Links
Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
Date:5/5/2008

Presentation Scheduled for Wednesday, May 7th at 9:30am EDT

NEW YORK, May 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, is scheduled to present at the Deutsche Bank 33rd Annual Health Care Conference in Boston, Massachusetts.

Mr. Weiss' presentation, which will take place on Wednesday, May 7th at 9:30am EDT, will be webcast live and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell surviva
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals Receives Nasdaq Notification
2. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
3. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
4. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
5. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
7. Keryx Biopharmaceuticals Announces Additions to Management Team
8. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
11. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 zFlo Motion ... pleased to announce an exciting product from a new partner. ... analysis solutions over the past 15 years, with offerings in ... recently, their 3D IMU system (inertial measurement unit), iSen, is ...
(Date:1/22/2015)... 2015 Diagenode, Inc., a leading ... Bioruptor® and complete solutions for epigenetics research, recently ... alleviating the need for manual processing. The new ... ChIP of histones or transcription factors and a ...
(Date:1/22/2015)... CAMBRIDGE, Mass. , Jan. 22, 2015   GenoSpace , ... suite of tools to enable the broad use of genomic, ... today announced the appointment of Michelle Munson , CEO ... independent director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 PlasmaTech ... care in critical areas, announced the closing of an underwritten ... to purchase up to an aggregate 3,500,000 shares of common ... $.01 per warrant.  The warrants have a per share exercise ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... PLYMOUTH MEETING, Pa., Sept. 28 /PRNewswire-FirstCall/ - Genaera,Corporation (Nasdaq: ... D.,Kaye, CEO of Xmark Asset Management LLC ("Xmark"), to ... Wolfe, Ph.D., as Executive Vice,President and Chief Scientific Officer, ... and Chief Medical Officer. "We are pleased to ...
... Sept. 28 VaxGen,Inc. (Pink Sheets: VXGN) announced ... Board of Directors as a result of accepting ... has required that Mr.,Anthony relinquish all corporate directorships ... immediately. (Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO ) "On ...
... DIEGO, Sept. 28 CardioDynamics (Nasdaq:,CDIC), the innovator ... announced the Company has received market clearance from,the ... ICG clinical parameters,and electronic medical record (EMR) interface ... is the product of a co-development partnership between,the ...
Cached Biology Technology:Genaera Elects New Board Member and Announces Executive Appointments 2Genaera Elects New Board Member and Announces Executive Appointments 3Genaera Elects New Board Member and Announces Executive Appointments 4Jack Anthony to Resign From VaxGen's Board After Accepting CEO Position at Osprey Pharmaceuticals 2CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility 2CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility 3
(Date:12/22/2014)... Dec. 22, 2014  The 2014 Holiday Season may be ... Market Intelligence reports that the long anticipated floodgates for ... intensifying demand for smart phones, tablets, and wearable mobile ... of 2.5 billion users with nearly 4.8 billion biometric ...
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the leading personal genetics ... fine-scale differences in genetic ancestry of individuals from across ... first arrived more than four hundred years ago, ... place for peoples from different continents. This study illuminates how ...
(Date:12/17/2014)... , Dec. 15, 2014 The Defense Logistics ... to detect and prevent counterfeit microcircuits from entering into ... performing an in-house microcircuit anti-counterfeit initiative dubbed DNA marking. ... while increasing their reliability throughout the supply chain. The ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... Mich. (July 8, 2009) Van Andel ... could be an important therapeutic target in the treatment ... patients with these cancers have few treatment options. ... cancers that don,t respond to traditional treatments tend to ...
... self-organizing systems are the Holy Grails of nanotechnology, but ... years. A team of scientists has taken a unique ... able to assemble into clusters that direct cell movement ... valuable insight into how complex periodic patterns in biological ...
... Prize will be given to Dr. Brian Shaw, Texas A&M ... in Snowbird, Utah. The honor based on quality, ... as the Outstanding Early-Career Mycologist Award of the Mycological Society ... four review papers in 12 years. Both the National Science ...
Cached Biology News:Possible drug target found for one of the most aggressive breast cancers 2Spontaneous assembly 2Spontaneous assembly 3Spontaneous assembly 4
... Fujifilm Life Science FLA-8000 Fluorescent Image Analyzer ... a single laser imaging system. This powerful ... labeled with fluorescent dyes or radioisotopes at ... demanding laboratories. Speed, image quality and flexibility ...
... cover slips for in situ hybridization,in ... on glass slides., Constant probe ... not adsorb probes. , Ready-to-use-Hybri-slips do ... , Avoid RNA degradation-Hybri-slips are supplied ...
...
...
Biology Products: